Eli Lilly and Co
LLY
Company Profile
Business description
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Contact
Lilly Corporate Center
IndianapolisIN46285
USAT: +1 317 276-2000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
47,000
Eli Lilly and Co News & Analysis
stocks
Eli Lilly earnings: Weak Orforglipron obesity data weighs down a strong quarter
With today’s share drop, we think Lilly stock looks fairly valued.
markets
June 2025 US stock market outlook: Has the storm passed?
Be wary of the recent complacency; there’s turbulent water ahead before the skies clear.
markets
US stock market outlook: Where we see opportunities in Q2
A bear market in AI stocks leads to more attractive valuations.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,915.70 | 38.20 | 0.43% |
| CAC 40 | 8,122.90 | 47.19 | -0.58% |
| DAX 40 | 23,672.83 | 203.72 | -0.85% |
| Dow JONES (US) | 47,147.48 | 309.74 | -0.65% |
| FTSE 100 | 9,686.92 | 11.45 | -0.12% |
| HKSE | 26,384.28 | 188.18 | -0.71% |
| NASDAQ | 22,900.59 | 30.23 | 0.13% |
| Nikkei 225 | 50,323.91 | 52.62 | -0.10% |
| NZX 50 Index | 13,499.04 | 34.58 | 0.26% |
| S&P 500 | 6,734.11 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,636.40 | 32.30 | 0.38% |
| SSE Composite Index | 3,972.03 | 18.46 | -0.46% |